Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Treo Ventures, founded in 2018, is a venture capital firm focused on advancing medical device and digital health innovations that address significant unmet clinical needs. The firm operates out of the United States and Ireland, with offices located in Silicon Valley and Dublin. Founders Mudit Jain, PhD, and Brad Vale, PhD, DVM, bring extensive experience in healthcare investing and operational roles, having collectively invested in over 40 companies globally.
The firm has established itself as a key player in the medical technology sector, leveraging its expertise to support transformative technologies. Treo Ventures operates the NuXcel medical device accelerator, which plays a crucial role in developing novel medical technologies. The firm’s commitment to fostering innovation is evident in its diverse portfolio, which includes ten notable companies.
Treo Ventures invests primarily in medical technology companies that tackle large unmet clinical needs. Their investment strategy encompasses both early-stage investments, where feasibility has been demonstrated, and later-stage investments supported by clinical data. The firm targets opportunities within the healthcare, digital health, and biotech sectors, focusing on innovations that can significantly impact patient care.
Geographically, Treo Ventures concentrates its efforts in the United States and Europe, allowing them to tap into a broad range of medical technology advancements. The firm also supports opportunities generated by its medical device accelerator, NuXcel, which enhances their ability to identify and nurture promising innovations in the medical technology space.
Treo Ventures has a diverse portfolio of ten notable companies, each contributing to advancements in medical technology:
Mudit K. Jain, PhD - General Partner. Mudit has extensive experience in healthcare investing and has led numerous successful investments in medical technology.
Brad H. Vale, PhD, DVM - General Partner. Brad brings a unique perspective with his background in veterinary medicine and healthcare investing, contributing to the firm's strategic direction.
Tracy Pappas - General Partner. Tracy has a strong track record in venture capital and operational roles, focusing on supporting portfolio companies in their growth.
Dave Shanahan, BSc - Venture Partner. Dave's expertise in medical technology and investment strategy enhances the firm's ability to identify promising opportunities.
To pitch Treo Ventures, founders should use the contact form available on their website at treovp.com. It is essential to include a comprehensive pitch deck that outlines the technology, market opportunity, and clinical data. Treo Ventures prefers detailed presentations that clearly articulate the problem being addressed and the solution offered.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are beneficial but not strictly necessary for submission.
Treo Ventures operates the NuXcel medical device accelerator, which supports the development of novel medical technologies. This program is designed to help early-stage companies refine their products and business models, providing access to resources, mentorship, and potential funding opportunities.
Eligibility for the NuXcel program typically includes startups focused on medical devices and digital health innovations that address significant clinical needs. Interested founders can apply through the Treo Ventures website.
In recent months, Treo Ventures has continued to expand its portfolio, focusing on innovative medical technologies. The firm has highlighted its commitment to supporting companies like CVRx, which received FDA's Breakthrough Device designation for its Barostim device, showcasing Treo's active role in fostering advancements in cardiovascular therapies.
Additionally, Treo Ventures has been promoting its medical device accelerator, NuXcel, which plays a crucial role in developing novel medical technologies. This initiative has attracted attention from startups looking to innovate in the healthcare space.
What are Treo Ventures' investment criteria?
Treo Ventures invests in medical technology companies that address significant unmet clinical needs, focusing on both early-stage and later-stage investments. They look for innovations with demonstrated feasibility and clinical data supporting efficacy.
How can I pitch Treo Ventures?
Founders can pitch Treo Ventures through their website at treovp.com. It is advisable to include detailed information about the technology, market potential, and clinical data in the pitch deck.
What makes Treo Ventures different from other investors?
Treo Ventures specializes in medical technology and has a dedicated accelerator, NuXcel, which supports the development of novel medical technologies. Their focus on addressing unmet clinical needs sets them apart in the venture capital landscape.
What is the geographic scope of Treo Ventures?
The firm primarily invests in the United States and Europe, allowing them to tap into a wide range of medical technology advancements.
What is the typical check size for investments?
While specific check sizes are not disclosed, Treo Ventures invests across various stages, including pre-seed, seed, Series A, and Series B, indicating a flexible approach to funding.
What kind of post-investment involvement does Treo Ventures have?
Treo Ventures actively supports its portfolio companies through mentorship, operational guidance, and access to their accelerator resources, enhancing the development pipeline for medical technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.